Article Text

Download PDFPDF

Identification of tumor-specific T cell receptors from primary tumor-infiltrating lymphocytes
  1. Hiroyuki Kishi1,
  2. Hiroshi Hamana1,
  3. Kiyomi Shitaoka1 and
  4. Atsushi Muraguchi1
  1. Aff1 grid.267346.2000000012171836XUniversity of Toyama Toyama Japan

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Antigen-specific adaptive T cell therapy or T cell receptor (TCR) gene therapy is promising as a next generation tumor therapy. For the therapy, the production of tumor-specific T cells or their TCRs is prerequisite. Exploration of tumor-associated antigens, antigen-specific T cells or their TCR is usually restricted to the population with major HLA haplotypes, such as HLA-A24 for the Southeast Asian or HLA-A2 for Caucasian population. In this context, antigen-specific T cell therapy or TCR gene therapy is restrictive to those with major HLA haplotypes but is not beneficial for those with minor HLA haplotypes. In this study, we analyzed the TCRαβ repertoire of tumor-infiltrating lymphocytes (TIL) of B16F10 melanoma in C57BL/6 mice at single cell levels. We found the clonal expansion of T cells in TILs, but not in splenic T cells and detected tumor-specific T cells in those clonally expanded cells. Our single cell analysis system may greatly contribute to analyze tumor-specific T cells without restriction in HLA haplotypes, thus leading to personalized tumor immunotherapy in the future.